Therapeutics and COVID-19: living guideline - 16 September 2022
Geneve; WHO; Sept. 16, 2022. 141 p. ilus, tab, graf. (WHO/2019-nCoV/therapeutics/2022.5).
non conventionnel
Dans Anglais
| BIGG, LILACS
| ID: biblio-1393164
ABSTRACT
The WHO Therapeutics and COVID-19 living guideline contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the 'Download' button) and via an online platform, and is updated regularly as new evidence emerges. This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients with severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.
Sujets)
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
COVID-19
Type d'étude:
Guide de pratique
Limites du sujet:
Humains
langue:
Anglais
Année:
2022
Type:
non conventionnel
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS